Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(135 products)
- CSF-1R(42 products)
- EGFR(561 products)
- Ephrin Receptor(25 products)
- FLT(89 products)
- Fibroblast Growth Factor Receptor (FGFR)(177 products)
- HER(5 products)
- Hck(3 products)
- IGF-1R(99 products)
- PDGFR(127 products)
- PYK2(7 products)
- Src(82 products)
- TAM Receptor(34 products)
- Tie-2(20 products)
- Trk receptor(53 products)
- Tyrosine Kinases(16 products)
- VEGFR(239 products)
- c-Fms(105 products)
- c-Kit(113 products)
- c-Met/HGFR(137 products)
- c-RET(61 products)
Show 13 more subcategories
Found 1048 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Color and Shape:SolidEGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formula:C19H21N3O2SColor and Shape:SolidMolecular weight:355.45TRK-IN-28
CAS:TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].Formula:C27H25F2N7Color and Shape:SolidMolecular weight:485.53Juvenile hormone B 3 (mixture of diastereomers)
CAS:Juvenile hormone B 3 (Juvenile hormone III bisepoxide) (mixture of diastereomers) is a sesquiterpenoid hormone. It can be isolated from the corpora allata (CA) of higher dipteran insects such as fruit flies and Drosophila melanogaster. This hormone exhibits anti-metamorphic activity and induces the expression of Kr-h1 by directly interacting with juvenile hormone (JH) receptors (Met and Gce). Juvenile hormone B 3 (mixture of diastereomers) is applicable in insect lethality studies.Formula:C16H26O4Color and Shape:SolidMolecular weight:282.38LSD1/EGFR-IN-1
CAS:LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.
Formula:C21H20ClN3O4Color and Shape:SolidMolecular weight:413.854EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Color and Shape:SolidKIN-8741
CAS:KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.Formula:C26H23F2N3O6Color and Shape:SolidMolecular weight:511.47UniPR500
CAS:UniPR500, a derivative of UniPR129, is a competitive antagonist for the EphA2 receptor, with a Ki of 0.78 μM. It reduces the binding of biotinylated Ephrin-A1 to EphA2 in a dose-dependent manner, exhibiting an IC50 value of 1.1 μM.Formula:C36H51N3O4Color and Shape:SolidMolecular weight:589.808EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColor and Shape:SolidMolecular weight:255.275TRK-IN-26
CAS:TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].Formula:C30H22F2N6O4Color and Shape:SolidMolecular weight:568.53HER2-IN-21
CAS:HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.
Formula:C20H18N4O3SColor and Shape:SolidMolecular weight:394.447Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formula:C10H8N2OColor and Shape:SolidMolecular weight:172.183TrkA-IN-9
CAS:TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.Formula:C31H32N4O4Color and Shape:SolidMolecular weight:524.61FMP-API-1
CAS:FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).Formula:C13H14N2O2Color and Shape:SolidMolecular weight:230.262D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Color and Shape:SolidMolecular weight:562.42EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Color and Shape:SolidMolecular weight:284.27Ligritinib
CAS:Ligritinib (AB801) is an orally active inhibitor of the AXL receptor tyrosine kinase. By inhibiting the kinase activity of AXL, Ligritinib blocks its downstream signaling pathways. It is utilized in cancer research, particularly in studies involving non-small cell lung cancer (NSCLC) in combination with chemotherapy.Formula:C33H32N6OColor and Shape:SolidMolecular weight:528.65EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColor and Shape:SolidMolecular weight:455.91N-Deshydroxyethyl Dasatinib-C3-NH2
CAS:N-Deshydroxyethyl Dasatinib-C3-NH2 is a target protein ligand-linker conjugate, comprising an LCK ligand and a PROTAC linker, designed to recruit E3 ligase. It is utilized in the synthesis of [PROTACSJ11646].Formula:C23H29ClN8OSColor and Shape:SolidMolecular weight:501.05EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formula:C27H31N7O3Color and Shape:SolidMolecular weight:501.58
